Literature DB >> 10385173

Subxyphoid access of the normal pericardium: a novel drug delivery technique.

R J Laham1, M Simons, D Hung.   

Abstract

The pericardial space may potentially serve as a drug delivery reservoir that might be used to deliver therapeutic substances to the heart. This study describes a novel delivery technique that enables safe and rapid percutaneous subxyphoid access of the normal pericardium in a large animal model (49 Yorkshire pigs). An epidural introducer needle (Tuohy-17) is advanced gently under fluoroscopic guidance with a continuous positive pressure of 20-30 mm Hg (achieved by saline infusion using an intraflow system). The positive pressure is intended to push the right ventricle (with a lower pressure) away from the needle's path. Entry of the pericardial space is suspected after an increase in the saline flow through the intraflow system. Access to the pericardial space is confirmed by the injection of 1 ml of diluted contrast under fluoroscopy. A soft floppy-tip 0.025" guidewire is then advanced to the pericardial space and the needle is exchanged for an infusion catheter. Access of the pericardial space was achieved in all animals without any adverse events and without any hemodynamic compromise even with the delivery of fluid volumes as large as 50 ml. Histologic examination in 15 animals 4 weeks after pericardial access did not reveal any delivery-related myocardial damage. The safety, ease, and absence of hemodynamic compromise make this technique a potentially useful method for intrapericardial drug delivery and a good alternative to standard pericardiocentesis in patients with small pericardial effusions at higher risk for complications.

Entities:  

Mesh:

Year:  1999        PMID: 10385173     DOI: 10.1002/(SICI)1522-726X(199905)47:1<109::AID-CCD24>3.0.CO;2-3

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  7 in total

1.  Therapeutic Angiogenesis for Coronary Artery Disease.

Authors:  Tanveer A. Khan; Frank W. Sellke; Roger J. Laham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

2.  Local epicardial inotropic drug delivery allows targeted pharmacologic intervention with preservation of myocardial loading conditions.

Authors:  Mark A Lovich; Abraham E Wei; Mikhail Y Maslov; Peter I Wu; Elazer R Edelman
Journal:  J Pharm Sci       Date:  2011-06-30       Impact factor: 3.534

3.  Nanoparticles administered intrapericardially enhance payload myocardial distribution and retention.

Authors:  Victor Segura-Ibarra; Francisca E Cara; Suhong Wu; David A Iruegas-Nunez; Sufen Wang; Mauro Ferrari; Arturas Ziemys; Miguel Valderrabano; Elvin Blanco
Journal:  J Control Release       Date:  2017-07-09       Impact factor: 9.776

4.  Myocardial drug distribution generated from local epicardial application: potential impact of cardiac capillary perfusion in a swine model using epinephrine.

Authors:  Mikhail Y Maslov; Elazer R Edelman; Matthew J Pezone; Abraham E Wei; Matthew G Wakim; Michael R Murray; Hisashi Tsukada; Iraklis S Gerogiannis; Adam Groothuis; Mark A Lovich
Journal:  J Control Release       Date:  2014-09-16       Impact factor: 9.776

5.  High concentrations of drug in target tissues following local controlled release are utilized for both drug distribution and biologic effect: an example with epicardial inotropic drug delivery.

Authors:  Mikhail Y Maslov; Elazer R Edelman; Abraham E Wei; Matthew J Pezone; Mark A Lovich
Journal:  J Control Release       Date:  2013-07-18       Impact factor: 9.776

6.  Increased shear stress with upregulation of VEGF-A and its receptors and MMP-2, MMP-9, and TIMP-1 in venous stenosis of hemodialysis grafts.

Authors:  Sanjay Misra; Alex A Fu; Alessandra Puggioni; Kamran M Karimi; Jaywant N Mandrekar; James F Glockner; Luis A Juncos; Bilal Anwer; Antonio M McGuire; Debabrata Mukhopadhyay
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-03-07       Impact factor: 4.733

7.  Simultaneous intra/extravascular administration of antiproliferative agents as a new strategy to inhibit restenosis: the peak of reactive cell proliferation as a hallmark for the duration of the treatment.

Authors:  Rainer Voisard; Eva Kucharczyk; Ute Deininger; Regine Baur; Vinzenz Hombach
Journal:  BMC Cardiovasc Disord       Date:  2002-01-18       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.